NO20073265L - Agonistananalog av amylin - Google Patents

Agonistananalog av amylin

Info

Publication number
NO20073265L
NO20073265L NO20073265A NO20073265A NO20073265L NO 20073265 L NO20073265 L NO 20073265L NO 20073265 A NO20073265 A NO 20073265A NO 20073265 A NO20073265 A NO 20073265A NO 20073265 L NO20073265 L NO 20073265L
Authority
NO
Norway
Prior art keywords
pro
ser
thr
amylin
asn
Prior art date
Application number
NO20073265A
Other languages
English (en)
Inventor
Elisabeth Albrecht
Howard Jones
Laura S L Gaeta
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20073265L publication Critical patent/NO20073265L/no
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Agonistanaloger av amylin som fremviser amylinagonistaktivitet er tilveiebragt.
NO20073265A 1991-11-19 2007-06-25 Agonistananalog av amylin NO20073265L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79426691A 1991-11-19 1991-11-19
PCT/US1992/009842 WO1993010146A1 (en) 1991-11-19 1992-11-19 Amylin agonist peptides and uses therefor

Publications (1)

Publication Number Publication Date
NO20073265L true NO20073265L (no) 1993-09-17

Family

ID=25162163

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19932603A NO324405B1 (no) 1991-11-19 1993-07-19 Agonistanalog av amylin og preparat omfattende denne.
NO20073265A NO20073265L (no) 1991-11-19 2007-06-25 Agonistananalog av amylin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19932603A NO324405B1 (no) 1991-11-19 1993-07-19 Agonistanalog av amylin og preparat omfattende denne.

Country Status (17)

Country Link
EP (2) EP1162207A1 (no)
JP (4) JP2902115B2 (no)
AT (1) ATE205854T1 (no)
AU (1) AU714439B2 (no)
CA (1) CA2100745C (no)
CZ (1) CZ288029B6 (no)
DE (1) DE69232064T2 (no)
DK (1) DK0567626T3 (no)
ES (1) ES2161697T3 (no)
FI (1) FI118601B (no)
GR (1) GR3036794T3 (no)
HK (1) HK1041891A1 (no)
MD (1) MD960317A (no)
NO (2) NO324405B1 (no)
RU (1) RU2130463C1 (no)
SK (1) SK88793A3 (no)
WO (1) WO1993010146A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
CN1134110A (zh) 1993-09-07 1996-10-23 安米林药品公司 调节胃肠动力的方法
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
JP4353544B2 (ja) * 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
GB0128583D0 (en) 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
AU2003278929A1 (en) 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
WO2004083243A1 (en) * 2003-03-18 2004-09-30 Applied Research Systems Ars Holding N.V. Amylin aggregation inhibitors and use thereof.
BRPI0518390A2 (pt) * 2004-10-26 2008-11-18 Lonza Ag mÉtodo de sÍntese de peptÍdeo, e respectivo peptÍdeo
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
KR101383493B1 (ko) 2005-03-31 2014-04-11 아스트라제네카 파마수티컬스 엘피 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및아밀린 효능제
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
EP2120985B1 (en) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 peptides for use in the treatment of psychotic and anxiety disorders
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
EP2405934B1 (en) 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
KR20160094956A (ko) 2013-11-05 2016-08-10 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물
US10072060B2 (en) 2014-05-02 2018-09-11 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
EP3271381B1 (en) 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin analogues
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
KR102130354B1 (ko) * 2019-08-14 2020-07-06 엘아이지넥스원 주식회사 코어 제거용 이형장치
US20240335513A1 (en) 2022-05-30 2024-10-10 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
AU631112B2 (en) * 1988-01-11 1992-11-19 Amylin Corporation Treatment of type 2 diabetes mellitus
ATE128032T1 (de) * 1989-07-10 1995-10-15 Amylin Pharmaceuticals Inc Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten.
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1992015317A1 (en) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues

Also Published As

Publication number Publication date
FI933252A0 (fi) 1993-07-16
AU3075392A (en) 1993-06-15
AU1245697A (en) 1997-03-27
NO932603L (no) 1993-09-17
ES2161697T3 (es) 2001-12-16
FI118601B (fi) 2008-01-15
EP0567626B1 (en) 2001-09-19
FI933252A (fi) 1993-08-23
SK88793A3 (en) 1994-12-07
NO932603D0 (no) 1993-07-19
HK1041891A1 (zh) 2002-07-26
JP2902115B2 (ja) 1999-06-07
CA2100745C (en) 2007-07-31
EP1162207A1 (en) 2001-12-12
WO1993010146A1 (en) 1993-05-27
GR3036794T3 (en) 2002-01-31
AU714439B2 (en) 2000-01-06
RU2130463C1 (ru) 1999-05-20
AU673147B2 (en) 1996-10-31
CA2100745A1 (en) 1993-05-20
MD960317A (ro) 1998-05-31
JP2006213716A (ja) 2006-08-17
ATE205854T1 (de) 2001-10-15
NO324405B1 (no) 2007-10-08
DE69232064D1 (de) 2001-10-25
DK0567626T3 (da) 2001-12-17
EP0567626A1 (en) 1993-11-03
JP2003238594A (ja) 2003-08-27
CZ288029B6 (cs) 2001-04-11
JP4018116B2 (ja) 2007-12-05
CZ168993A3 (en) 1994-04-13
DE69232064T2 (de) 2002-03-28
JPH11152299A (ja) 1999-06-08
JPH06504794A (ja) 1994-06-02

Similar Documents

Publication Publication Date Title
NO20073265L (no) Agonistananalog av amylin
CA2050300A1 (en) Tnf-inhibiting proteins and the preparation thereof
IL89541A0 (en) Urethane-protected amino acid-n-carboxyanhydrides and their use in the synthesis of polypeptides
AU1299088A (en) Transforming growth factor-beta
KR100295606B1 (no)
GB8821785D0 (en) Peptide compounds
EP0249477A3 (en) Functional recombinant analog polypeptides devoid of hydrophobic amino acids
EP0292257A3 (en) Peptides having anf activity
Huang et al. An antiplatelet peptide, gabonin, from Bitis gabonica snake venom
DE3751398D1 (de) Substrat-Peptide.
WO1999048908A3 (fr) POLYPEPTIDE IMMUNOREACTIF DU RECEPTEUR TrkA du NGF ET UTILISATIONS
DK262986A (da) Peptidmateriale med thymushumoral aktivitet
NO932491L (no) Analoger av piskin gnrh
EP0232435A3 (en) Serum thymic factor peptide analogs and a process for the preparation thereof
CA2083286A1 (en) Recombinant fibrinogenases, preparation and use thereof
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
EP0687685A4 (en) PHYSIOLOGICALLY ACTIVE PEPTIDES
DK200200302A (da) Rekombinante polypeptider omfattende aminosyresekvensen af moden vævsfaktorinhibitor (TFI), polypeptidfragmenter deraf, ekspressionsvektorer der koder for disse, værtsceller transformeret dermed, og fremgangsmåde til fremstilling af et ........
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
AU2913189A (en) Peptide corresponding to hiv-env 583-599, and analogs thereof and applications of the peptides
ES2069476A1 (es) Procedimiento de sintesis de peptidos con capacidad de detectar anticuerpos ant-virus de la hepatitis c (vhc) en suero de individuos afectados.
PT100299A (pt) Analogo de hirudina, metodo para a sua producao e anti-coagulante contendo-o, e vector de secrecao , microorganismos transformados com o referido vector e metodo para a producao de produtos a partir dos referidos microorganismos
DK411686A (da) Peptider

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application